Phase II, Open Label, Single Arm Study of the Efficacy and Safety of Crizotinib in East Asian Patients With Advanced ALK-Negative NSCLC Harboring a Translocation or Inversion Involving the c-ROS Oncogene (ROS1) Locus

Trial Profile

Phase II, Open Label, Single Arm Study of the Efficacy and Safety of Crizotinib in East Asian Patients With Advanced ALK-Negative NSCLC Harboring a Translocation or Inversion Involving the c-ROS Oncogene (ROS1) Locus

Completed
Phase of Trial: Phase II

Latest Information Update: 06 Jul 2017

At a glance

  • Drugs Crizotinib (Primary)
  • Indications Non-small cell lung cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms The OxOnc Study
  • Sponsors OxOnc Development; Pfizer
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 17 Jun 2016 According to OxOnc Development media release, results from this trial were presented at the recent 2016 American Society of Clinical Oncology (ASCO) Annual Meeting.
    • 17 Jun 2016 Status changed from active, no longer recruiting to completed, according to OxOnc Development media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top